Replies to post #9877 on AEterna Zentaris Inc. (AEZS)

[Atlanta1]

book value has absolutely nothing to do with a developmental stage biotech

[downtrendbuyer]

Bashers tend to use lower estimates and worst possible sources :)

[SmokeSignals]

BOOK Value AEZS $1.31 clear as day on yahoo finance and etrade. POINTS OUT HOW UNDERVALUED THIS BIOTECH REALLY IS. FORGET ALL THE OTHER REASONS outside of the PR's which are incredible, BECAUSE THAT'S A FACT JACK!

[smolie]

In a research report issued today, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) with a $2 price target, after the company announced that its lead oncology compound, zoptarelin doxorubicin met the primary end-point of an investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer. The results were presented this morning at the European Cancer Congress in Vienna, Austria.